To relieve pets of itchy skin, veterinarians may prescribe the Zenrelia (Ilunocitinib) Tablets for Dogs. With a fast-acting formula, Zenrelia works to improve skin conditions starting day one of administration, including allergic dermatitis and atopic dermatitis. The flavorless formula allows for convenient feeding either mixed with their food or directly. Use Zenrelia for dogs ages 12 months and up.How it Works

Zenrelia blocks itch signals from reaching your dog's brain, reducing the sensation of itch.

Special Precautions

Dogs younger than 12 months of age, dogs with serious infections. Zenrelia has not been tested in dogs used for breeding, pregnant, or nursing dogs and has not been evaluated when used with drugs that may effect the immune system. See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.

Overdose Information

Contact your nearest emergency animal hospital.

Side Effects

Monitor your pet for any adverse reactions, including vomiting, diarrhea and lethargy. Contact your veterinarian with any questions you might have.

Storage

Store at room temperature between 15-25 ° (59 to 77°F).IMPORTANT SAFETY INFORMATION: See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit https://www.elancolabels.com/us/zenrelia.

WARNING

VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.